Evidence map›Paper›PMID 31250273›Full record

ArticleJournal of molecular neuroscience : MN2019

Klotho Is Neuroprotective in the Superoxide Dismutase (SOD1

Ella Zeldich, Ci-Di Chen, Emma Boden, Bryce Howat, Jason S Nasse, Dean Zeldich, Anthony G Lambert, Andrea Yuste, Jonathan D Cherry, Rebecca M Mathias and 5 more

Open access · greenAbstract read
In one paragraph

Article in Journal of molecular neuroscience : MN, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 45 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Frontiers in pharmacology · 2025
    Article
  13. Article
  14. Review
  15. Article
  16. [Research progress of metalloporphyrin against neurodegene-rative diseases].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2024
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Ella ZeldichDepartment of Biochemistry, Boston University School of Medicine, 72 East Concord Street, Boston, MA, 02118, USA.
Ci-Di ChenDepartment of Biochemistry, Boston University School of Medicine, 72 East Concord Street, Boston, MA, 02118, USA.
Emma BodenDepartment of Biochemistry, Boston University School of Medicine, 72 East Concord Street, Boston, MA, 02118, USA.
Bryce HowatDepartment of Biomedical Engineering, Boston University, Boston, MA, USA.
Jason S NasseDepartment of Biochemistry, Boston University School of Medicine, 72 East Concord Street, Boston, MA, 02118, USA.
Dean ZeldichDepartment of Biomedical Engineering, Boston University, Boston, MA, USA.
Anthony G LambertDepartment of Biomedical Engineering, Boston University, Boston, MA, USA.
Andrea YusteKlogene Therapeutics, Inc., Boston, MA, USA.
Jonathan D CherryDepartment of Neurology, Boston University School of Medicine, Boston, MA, USA.
Rebecca M MathiasDepartment of Neurology, Boston University School of Medicine, Boston, MA, USA.
Qicheng MaDepartment of Biochemistry, Boston University School of Medicine, 72 East Concord Street, Boston, MA, 02118, USA.
Nelson C LauDepartment of Biochemistry, Boston University School of Medicine, 72 East Concord Street, Boston, MA, 02118, USA.
Ann C McKeeDepartment of Neurology, Boston University School of Medicine, Boston, MA, USA.
Theo HatzipetrosALS Therapy Development Institute, Cambridge, MA, USA.
Carmela R AbrahamDepartment of Biochemistry, Boston University School of Medicine, 72 East Concord Street, Boston, MA, 02118, USA. cabraham@bu.edu.ORCID http://orcid.org/0000-0002-6649-1960
Boston University · USAmyotrophic Lateral Sclerosis Therapy Development Institute · USKlogene (United States) · US

Funding

STRUCTURAL STUDIES IN THE CENTRAL NERVOUS SYSTEMP01AG000001 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ROSENE, DOUGLAS L · 1985 to 2013
$20.7M
XI INTERNATIONAL SYMPOSIUM ON AMYLOIDOSISP41RR010888 · NCRR · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ZAIA, JOSEPH · 1996 to 2011
$18.6M
Multidisciplinary Training in Cardiovascular ResearchT32HL007224 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI HAMBURG, NAOMI MIRIAM, WAINFORD, RICHARD DAVID · 1985 to 2020
$12.3M
Transposon landscapes and transcriptome diversity in aging neuronsR01AG052465 · NIA · BRANDEIS UNIVERSITY · PI LAU, NELSON C · 2016 to 2020
$2.0M
Discovery of probes that enhance expression of the neuroprotective protein KlothoR56AG051638 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ABRAHAM, CARMELA R, HODGETTS, KEVIN · 2016 to 2016
$856k
NCRR NIH HHS P41 RR010888NHLBI NIH HHS T32 HL007224NIA NIH HHS P01 AG000001NIA NIH HHS R01 AG052465NIA NIH HHS R56 AG051638
6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by the loss of motor neurons in the brain and spinal cord. ALS neuropathology is associated with increased oxidative stress, excitotoxicity, and inflammation. We and others reported that the anti-aging and cognition-enhancing protein Klotho is a neuroprotective, antioxidative, anti-inflammatory, and promyelinating protein. In mice, its absence leads to an extremely shortened life span and to multiple phenotypes resembling human aging, including motor and hippocampal neurodegeneration and cognitive impairment. In contrast, its overexpression extends life span, enhances cognition, and confers resistance against oxidative stress; it also reduces premature mortality and cognitive and behavioral abnormalities in an animal model for Alzheimer's disease (AD). These pleiotropic beneficial properties of Klotho suggest that Klotho could be a potent therapeutic target for preventing neurodegeneration in ALS. Klotho overexpression in the SOD1 mouse model of ALS resulted in delayed onset and progression of the disease and extended survival that was more prominent in females than in males. Klotho reduced the expression of neuroinflammatory markers and prevented neuronal loss with the more profound effect in the spinal cord than in the motor cortex. The effect of Klotho was accompanied by reduced expression of proinflammatory cytokines and enhanced the expression of antioxidative and promyelinating factors in the motor cortex and spinal cord of Klotho × SOD1 compared to SOD1 mice. Our study provides evidence that increased levels of Klotho alleviate ALS-associated pathology in the SOD1 mouse model and may serve as a basis for developing Klotho-based therapeutic strategies for ALS.

Indexed as

Amyotrophic Lateral SclerosisAnimalsCells, CulturedCytokinesFemaleGlucuronidaseKlotho ProteinsLongevityMaleMiceMice, Inbred C57BLMotor CortexNeurogliaNeuronsSuperoxide Dismutase-1CytokinesGlucuronidaseKlotho ProteinsSuperoxide Dismutase-1Amyotrophic lateral sclerosisMicrogliaMotor neuronsNeurodegenerationNeuroinflammationTherapeutics

Identifiers

PMID31250273
PMCPMC7008951
OpenAlexW2954713993

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.